Creatine for Parkinson
Verdict: Counter-Evidence
Across 4 PubMed studies, the evidence for Creatine in Parkinson grades Tier D — counter-evidence. High-quality evidence indicates it is not effective (or is harmful) for this use.
D 🔴 D Counter-Evidence Counter-Evidence
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.27
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
83%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.269
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (4)L2 · primary research & systematic reviews
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial (NET-PD LS-1)
Finding: The trial was terminated early for futility: at the planned interim analysis (n=955) the global statistical test was t1865.8 = -0.75 (2-sided P = .45), with mean summed ranks of 2360 (placebo) vs 2414 (creatine) and no detectable difference in adverse events.
View on PubMed Creatine for Parkinson's disease (Cochrane Systematic Review)
Finding: Pooling 2 RCTs (n=194) found no clear effect on motor function (MD -0.26, 95% CI -4.39 to 3.88) or ADL (MD 0.37, 95% CI -1.28 to 2.02), both low-quality evidence, with higher gastrointestinal side-effect rates at 2-year follow-up.
View on PubMed The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials
Finding: Across 5 RCTs (n=1339) there were no significant differences between creatine and control in total, mental, ADL or motor UPDRS scores, with only a marginal improvement seen on the Schwab & England Scale.
View on PubMed Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease
Finding: Pooling 3 RCTs (n=1935) the overall effect favored neither group on UPDRS total (MD 1.07, 95% CI -3.38 to 1.25), UPDRS III (MD 0.62, 95% CI -2.27 to 1.02), UPDRS II (MD 0.03) or UPDRS I (MD 0.03), so current evidence does not support creatine for neuroprotection against PD.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
FDA has no questions source↗
L4b EU EFSA
Supportive
cause and effect relationship has been established source↗
L4c UK NHS
Not addressed
Supplements containing creatine are widely used by athletes to improve performance source↗
L5a NIH Office of Dietary Supplements
Supportive
May increase strength, power source↗
L5b Mayo Clinic
Cautious
In one large study of people with Parkinson's disease who took creatine, those who consumed more than 300 mg of caffeine a day had faster progression of Parkinson's disease. More research is needed. source↗
L5c Cleveland Clinic
Cautious
Neurodegenerative diseases, such as muscular dystrophy, Parkinson's disease and Huntington's disease [may benefit from creatine supplements]. Studies suggest that creatine supplements may help brain function in people 60 and older. This includes: Short-term memory. Reasoning. Neuroprotection (keeping groups of nerve cells safe from injury or damage). source↗
L5d Harvard Health
Cautious
Some small studies have suggested that creatine might be helpful for those with a few diseases that afflict older people, such as heart failure and Parkinson's disease. source↗
L5e Specialty Society (condition-mapped)
Against
In Parkinson's, researchers have investigated certain supplements, such as creatine, coenzyme Q, inosine and vitamin E. (Unfortunately none demonstrated benefit.) source↗